排序方式: 共有26条查询结果,搜索用时 15 毫秒
1.
目的:探讨狂犬疫苗接种后不良反应的一般规律及特点,为观察狂犬疫苗不良反应提供参考。方法检索1975~2014年中国知网中公开报道的有关狂犬疫苗不良反应的个案病例报道,并进行分类统计与分析。结果共检索到173篇符合标准的文献,合计1855例;在本次统计的病例中,不良反应以20~40岁居多,占40.92%。不良反应多发生于注射后1~12 h内,达到45.56%,以第1、3、4针较多。Vero细胞培养的疫苗不良反应发生率最高,构成比为54.49%,多为皮肤系统疾病;其次为原代地鼠肾细胞培养的疫苗不良反应,构成比为41.46%,多为过敏反应。动物脑组织狂犬疫苗以神经系统并发症为主,构成比为3.49%。结论狂犬疫苗引起不良反应的原因较多,临床应加以重视,在接种时和接种后都应密切监察,以减少不良反应的发生并及时抢救。 相似文献
2.
氯沙坦治疗原发性高血压临床疗效观察 总被引:3,自引:0,他引:3
童宁 《现代中西医结合杂志》2007,16(9):1174-1175
目的观察氯沙坦治疗高血压的临床疗效。方法选择门诊符合高血压病诊断的49例患者,随机分为2组:氯沙坦组口服氯沙坦50 mg,1次/d;卡托普利组口服卡托普利12.5 mg,3次/d。2组各服药4周。记录治疗期间发生的不良反应,同时记录偶测血压,并行动态血压监测。结果氯沙坦组总有效率(90%)明显优于卡托普利组(76%),有显著性差异(P<0.05);氯沙坦组治疗后的偶测血压和24 h动态血压降低程度优于卡托普利组,有显著性差异(P<0.05)。结论氯沙坦对轻中度高血压降压效果良好,且无明显不良反应。 相似文献
3.
4.
Xu Kai-ye徐开茔 Tang Ao-rong唐敖荣 Shi Bing-zhang史秉璋 Xiang Qi杨琦 Huang Wei-li黄伟立¨ Lian Yang-de廉养德 Shi You-zheng施有政 Tong Ning-sheng童宁生 Chen Guo-jie陈国杰 Qu Feng-ying区凤英 Xi Shun-lai奚顺来 《中华医学杂志(英文版)》1986,99(4):277-280
We studied the relationship between breast
parenchymal pattern and the incidence of breast
cancer. The material included l,564 normal subjects
of a mass survey and 552 pathologically proved
cases. The incidence of breast parenchymal pattems
of the two groups was compared and no relation-
ship was shown between dense type and breast
cancer. The "high risk group" opinion remains to
be proved. We find that clinical management of
breast disease and mass surveys can not be based
on breast X-ray parenchymal pattern. 相似文献
5.
早期应用辛伐他汀干预不稳定型心绞痛的疗效观察 总被引:1,自引:0,他引:1
童宁 《现代中西医结合杂志》2007,16(3):322-323
目的观察不稳定型心绞痛患者早期应用辛伐他汀的疗效。方法将59例诊断为不稳定型心绞痛的患者随机分为治疗组和对照组,对照组予常规治疗,治疗组在常规治疗的基础上加用辛伐他汀10 mg/d,疗程3个月。分别于治疗前后查血脂,对比治疗后血脂水平及临床心脏事件发生情况。结果与对照组比较,治疗组治疗3个月后TC和LDL-C下降明显,心血管事件发生率低,有显著性差异(P均<0.05)。结论不稳定型心绞痛患者早期使用辛伐他汀治疗可降低血脂水平,降低主要心血管事件发生率。 相似文献
6.
目的 探讨高原地区房间隔缺损(ASD)患者血浆脑钠肽(BNP)及内皮素(ET-1)浓度的变化以及与肺动脉压力间的关系.方法 105例患者确诊为单纯房间隔缺损(ASD),分为ASD并肺动脉高压组(ASD-PH)和ASD无肺动脉高压组(ASD-nPH),ASD-PH组又分为ASD并轻度肺动脉高压和ASD并中重度肺动脉高压组.所有患者按居住地海拔分2000~2 500m组、2 501~3 500m组及>3500m组.放射免疫法测定血浆BNP浓度,ELISA法测定ET-1.结果 ASD-PH组患者血清BNP、ET-1的水平明显高于ASD-nPH组,分别为(152.34±40.61) pg/ml对(126.70±32.27) pg/ml和(137.69±37.17)pg/ml对(92.92±32.3) pg/ml.不同程度肺高压患者的血浆BNP及ET-1水平存在显著差异(F=6.782,P<0.05;F=8.475,P<0.05).不同海拔ASD患者血浆BNP及ET-1亦存在显著差异(F=6.846,P<0.05;F=9.327,P<0.05).ASD患者血浆BNP与平均肺动脉压(mPAP)及缺损大小正相关(分别为r=0.326,P<0.05和r=0.301,P<0.05),与患者居住海拔呈正相关(r=0.252,P<0.05).结论 ASD-PH组患者血清BNP、ET-1的水平明显高于ASD-nPH组,随着肺动脉高压程度的增加及海拔的上升二者均升高,ET、BNP共同参与了肺动脉高压的发生发展,低氧环境促进了ET、BNP的分泌. 相似文献
7.
8.
目的:分析质量控制在临床免疫检验中的作用.方法:将2018年1月至2019年7月在本院实施免疫检验的78例患者视为研究对象,以电脑随机编号法划入常规组与质控组(n=39).常规组实施常规检测,质控组在此基础上实施免疫检验分析质量控制干预,比较患者的免疫检验平均变异指数及患者检验期间的工作满意率.结果:质控组患者的CEA、AFP、CA125及CA199变异指数均低于常规组患者,两组数据比较有统计学意义(P<0.05).常规组患者对检验工作实施的满意率为79.49%,质控组患者对检验工作实施的满意率为97.44%,质控组患者的满意率更高(P<0.05).结论:质量控制在临床免疫检验中的使用,能够降低免疫检验中各类指标的变异指数,提升患者的免疫检验工作满意率. 相似文献
9.
目的了解南京市第二医院门诊药房2014—2018年水飞蓟类保肝药物的门诊使用情况,分析该类药物的使用特点和趋势,为临床合理用药和科学管理提供参考。方法收集南京市第二医院2014—2018年水飞蓟类药物的门诊使用资料,对消耗量、销售金额、用药频度(DDDs)、日均费用(DDC)等进行整理分析。结果 2014—2018年,水飞蓟类保肝药物中年消耗量最高的是水飞蓟宾葡甲胺,但从2016年开始逐年降低,至2018年仍占48.75%;销售金额和DDDs值排名最高的是水飞蓟素,其从2015年开始逐年上升,至2018年销售金额占37.88%;5年内益肝灵液体胶囊的DDC值一直最高,其日治疗费用达到8.12;复方益肝灵的消耗量、销售金额、DDDs和DDC均处于最低值,其2018年的消耗量占比仅为0.21%。结论南京市第二医院门诊治疗肝炎以纯度较高和价格适中的水飞蓟宾、水飞蓟素以及水飞蓟宾葡甲胺这3种药物为主,这与其适宜的价格和适宜的用药频度是一致的。 相似文献
10.
Aim To explore the effects of corilagin on non-alcoholic fatty liver disease induced by high-fat and high-sugar diet in mice via regulating AMPK-autophagy signaling. Methods Healthy 8-week-old male C57BL/6J mice were randomly divided into control group, model group and corilagin group. The mice of model group and corilagin group were fed with a high-fat and high-sugar diet for four weeks at the age of eight weeks. The corilagin group mice were also intraperitoneally injected with corilagin (20 mg • k g - 1 ), which was given once every 2 days for 4 weeks. The mice of the control group and the model group were given equal dose of normal saline. After modeling and administration, the mice were sacrificed and the liver weight recorded. The liver pathological changes of each group mice were assessed by HE staining, oil red O staining and Masson staining. The biochemical indexes in serum and liver tissue were detected by the ELISA kit. The p-AMPK and autophagy levels were detected by Western blot. Results The results showed that compared to control group, the liver weight of the model group increased, the AST and ALT levels in serum also significantly increased, there were a large number of fat vacuoles and severe lipid deposition and mild collagen fibrosis in liver, while the liver weight and TG level in liver significantly decreased, and the liver pathological changes were significantly improved after treated with corilagin. Western blot results showed the levels of autophagy related proteins such as Atg7 and Atg5 significantly decreased in the model group, and the p-AMPK level also significantly decreased. When treated with corilagin, p-AMPK and the autophagy levels were up-regulated. Conclusion corilagin can protect non-alcoholic fatty liver disease in mice induced by high fat and high sugar diet. The mechanism may involve increasing p-AMPK level and enhancing autophagy level in liver. © 2023 Publication Centre of Anhui Medical University. All rights reserved. 相似文献